Format

Send to

Choose Destination
Epigenomics. 2017 Jul;9(7):997-1011. doi: 10.2217/epi-2017-0018. Epub 2017 Jun 27.

Cellular reprogramming technology for dissecting cancer epigenome in vivo.

Author information

1
Center for iPS Cell Research & Application, Kyoto University, Kyoto 606-8507, Japan.

Abstract

Decades of studies have shown that epigenetic alterations play a significant role on cancer development both in vitro and in vivo. However, considering that many cancers harbor mutations at epigenetic modifier genes and that transcription factor-mediated gene regulations are tightly coupled with epigenetic modifications, the majority of epigenetic alterations in cancers could be the consequence of the dysfunction or dysregulation of epigenetic modifiers caused by genetic abnormalities. Therefore, it remains unclear whether bona fide epigenetic abnormalities have causal roles on cancer development. Reprogramming technologies enable us to actively alter epigenetic regulations while preserving genomic information. Taking advantage, recent studies have provided in vivo evidence for the significant impact of epigenetic abnormalities on the initiation, maintenance and progression of cancer cells.

KEYWORDS:

Wilms’ tumor; cancer epigenetics; dedifferentiation; in vivo reprogramming; induced pluripotent stem cells

PMID:
28651445
DOI:
10.2217/epi-2017-0018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center